The stock of Osiris Therapeutics, Inc. (NASDAQ:OSIR) is a huge mover today! About 452,338 shares traded hands or 610.95% up from the average. Osiris Therapeutics, Inc. (NASDAQ:OSIR) has declined 23.51% since April 5, 2016 and is downtrending. It has underperformed by 25.46% the S&P500.
The move comes after 9 months positive chart setup for the $177.81M company. It was reported on Nov, 8 by Barchart.com. We have $9.85 PT which if reached, will make NASDAQ:OSIR worth $168.92 million more.
Osiris Therapeutics, Inc. (NASDAQ:OSIR) Ratings Coverage
Out of 8 analysts covering Osiris Therapeutics (NASDAQ:OSIR), 5 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 63% are positive. Osiris Therapeutics has been the topic of 13 analyst reports since August 6, 2015 according to StockzIntelligence Inc. TH Capital initiated Osiris Therapeutics, Inc. (NASDAQ:OSIR) on Friday, November 6 with “Buy” rating. Citigroup initiated the shares of OSIR in a report on Monday, November 16 with “Buy” rating. The stock of Osiris Therapeutics, Inc. (NASDAQ:OSIR) earned “Neutral” rating by Chardan Capital Markets on Monday, November 2. The stock of Osiris Therapeutics, Inc. (NASDAQ:OSIR) earned “Sell” rating by Zacks on Monday, August 31. Canaccord Genuity initiated the shares of OSIR in a report on Monday, November 16 with “Buy” rating. The stock of Osiris Therapeutics, Inc. (NASDAQ:OSIR) has “Buy” rating given on Monday, November 16 by Goldman Sachs. The stock of Osiris Therapeutics, Inc. (NASDAQ:OSIR) earned “Hold” rating by Zacks on Tuesday, August 25. The rating was downgraded by Brean Capital to “Sell” on Tuesday, November 17. The stock of Osiris Therapeutics, Inc. (NASDAQ:OSIR) has “Outperform” rating given on Friday, December 4 by Wells Fargo. The rating was upgraded by Zacks on Monday, September 7 to “Hold”.
According to Zacks Investment Research, “OSIRIS THERAPEUTICS, INC. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel for regenerating bone in orthopedic indications. Prochymal is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease and also Crohn’s disease, and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. Osiris also has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Osiris is a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products.”
Insitutional Activity: The institutional sentiment decreased to 1.07 in 2016 Q2. Its down 0.27, from 1.34 in 2016Q1. The ratio turned negative, as 13 funds sold all Osiris Therapeutics, Inc. shares owned while 15 reduced positions. 9 funds bought stakes while 21 increased positions. They now own 7.04 million shares or 2.88% less from 7.25 million shares in 2016Q1.
The New York-based D E Shaw And Commerce Inc has invested 0% in Osiris Therapeutics, Inc. (NASDAQ:OSIR). Natl Bank Of Montreal Can, a Ontario – Canada-based fund reported 19,860 shares. Strs Ohio reported 8,200 shares or 0% of all its holdings. Parametric Assocs has 12,201 shares for 0% of their US portfolio. Pnc Finance Svcs Gp has 0% invested in the company for 198 shares. State Board Of Administration Of Florida Retirement owns 23,569 shares or 0% of their US portfolio. Blackrock Fund Advsr reported 950,541 shares or 0% of all its holdings. The New York-based Goldman Sachs Group Inc has invested 0% in Osiris Therapeutics, Inc. (NASDAQ:OSIR). Schwab Charles Inv Mngmt has 53,481 shares for 0% of their US portfolio. Bancorp Of America Corp De has invested 0% of its portfolio in Osiris Therapeutics, Inc. (NASDAQ:OSIR). Globeflex L P has 57,303 shares for 0.08% of their US portfolio. Fmr Ltd Liability Corp last reported 0% of its portfolio in the stock. Baker Bros Advsrs Limited Partnership holds 499,193 shares or 0.03% of its portfolio. Proshare Advisors Ltd Com last reported 0% of its portfolio in the stock. California State Teachers Retirement Sys reported 41,684 shares or 0% of all its holdings.
More notable recent Osiris Therapeutics, Inc. (NASDAQ:OSIR) news were published by: Benzinga.com which released: “22 Stocks Moving In Tuesday’s Pre-Market Session” on November 08, 2016, also Businesswire.com with their article: “Osiris Therapeutics Announces an Addition to its Wound Care Portfolio, TruSkinâ„¢” published on November 02, 2015, Prnewswire.com published: “Shareholder Class Action Filed Against Osiris Therapeutics, Inc. – OSIR” on January 15, 2016. More interesting news about Osiris Therapeutics, Inc. (NASDAQ:OSIR) were released by: Fool.com and their article: “Why Osiris Therapeutics Is Crashing Today” published on November 17, 2015 as well as Marketwatch.com‘s news article titled: “Osiris Therapeutics discloses criminal investigation, stock plunges” with publication date: May 31, 2016.
OSIR Company Profile
Osiris Therapeutics, Inc., incorporated on March 30, 2010, is a cellular and regenerative medicine company. The Firm is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Firm operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Firm produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. All of these products are cryo-preserved and stored in special freezers at -80 degrees Celsius.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.